Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enveric Biosciences Inc (ENVB) vs iShares Core High Dividend ETF (HDV) Price & Performance

Enveric Biosciences IncTrade
iShares Core High Dividend ETFTrade

Price performance (Past 24H)

Key statistics

Enveric Biosciences Inc vs iShares Core High Dividend ETF — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while iShares Core High Dividend ETF trades at $29.2. The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.

ENVBHDV
Market Cap
$6.20M
Sector
Health
52-Week High
$17.40$29.14
52-Week Low
$1.27$23.64
Enterprise Value
$1.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enveric Biosciences Inc

ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.

Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.

iShares Core High Dividend ETF

HDV trades at $28.78, up 0.21% with a bullish technical signal. It yields approximately 3.1% from dividends, with recent payouts in June and July 2026. The ETF focuses on high-quality U.S. large-cap dividend stocks, outperforming the S&P 500 year-to-date by 9 percentage points. News highlights its appeal for retirement income and institutional buying, such as 180 Wealth Advisors increasing its stake by 386.2% in Q2 2026.

The outlook is positive due to strong dividend sustainability and defensive sector weighting, but risks include interest rate sensitivity and concentrated holdings. Analysts favor HDV for income-focused portfolios, citing its quality screening and lower volatility.

Returns comparison

Trailing returns across standard periods

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB

About iShares Core High Dividend ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.

Read more on HDV